Allianz Asset Management GmbH Sells 16,996 Shares of DexCom, Inc. $DXCM

Allianz Asset Management GmbH lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 56,083 shares of the medical device company’s stock after selling 16,996 shares during the period. Allianz Asset Management GmbH’s holdings in DexCom were worth $4,895,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Golden State Wealth Management LLC lifted its holdings in DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after buying an additional 264 shares during the period. Zions Bancorporation National Association UT bought a new stake in shares of DexCom during the first quarter worth about $27,000. Anderson Financial Strategies LLC bought a new stake in shares of DexCom during the first quarter worth about $37,000. Alpine Bank Wealth Management bought a new stake in DexCom in the 1st quarter worth about $40,000. Finally, Private Trust Co. NA grew its position in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after purchasing an additional 335 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on DXCM. UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Morgan Stanley increased their target price on shares of DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Stifel Nicolaus started coverage on shares of DexCom in a report on Tuesday. They issued a “buy” rating and a $85.00 price target on the stock. Argus initiated coverage on shares of DexCom in a report on Thursday, August 21st. They issued a “buy” rating and a $100.00 price target on the stock. Finally, Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $96.40.

Insider Buying and Selling at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the sale, the director directly owned 51,121 shares in the company, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,849 shares of company stock valued at $564,733. 0.32% of the stock is owned by corporate insiders.

DexCom Stock Up 0.5%

Shares of DexCom stock opened at $71.06 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock has a market capitalization of $27.87 billion, a PE ratio of 49.35, a price-to-earnings-growth ratio of 1.49 and a beta of 1.47. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The company has a 50-day simple moving average of $72.59 and a two-hundred day simple moving average of $77.71.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.